Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Sep 20, 2018-- Two Oral Presentations Highlighting Previously Reported Phase 2b STORM Data in Patients with Penta-Refractory Multiple Myeloma and Phase 2b SADAL Data in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma --
NEWTON, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced two oral presentations and one poster...
-
Sep 13, 2018-- Oral Selinexor Achieves 26.2% Overall Response Rate and Duration of Response of 4.4 Months in Overall Study Population; Responses Typically Occurred Within 1 Cycle (4 Weeks) of Treatment --
NEWTON, Mass., Sept. 13, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that updated clinical data from the Phase 2b...
-
Sep 4, 2018
NEWTON, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’
-
Sep 4, 2018-- Current Chief Executive Officer of Abeona Therapeutics, Inc. and former Executive Vice President and Chief Commercial Officer of Alexion Pharmaceuticals, Inc.; Brings Wealth of Leadership and Global Strategic Experience --
NEWTON, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the appointment of Carsten Thiel, Ph.D., to...
-
Aug 29, 2018
NEWTON, Mass., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that members of the Company’s management...